Research by Tissera Sponsored Scientific Team at the Weizmann Institute of Science, Published in the PNAS, Holds Hope for Treating Genetic Disease.

HERZLIYA, Israel -- Tissera, Inc. (OTCBB:TSSR) reports that Prof. Yair Reisner and his research team from the Weizmann Institute of Science published an article in the December 12, 2006 issue of PNAS (Proceedings of the National Academy of Sciences) entitled "Correcting Monogenic Diseases by Fetal Spleen Transplantation: Hemophilia as a Proof of Concept". The study may be obtained in PDF form from the PNAS website, www.pnas.org.

The team's research was predominantly supported by Tissera as part of its Research and Development Plan, which is based on the premise that ways might be found to utilize various porcine fetal tissues for transplantation into human patients in need. The Company's R&D efforts are directed towards developing and commercializing such transplantation technology, which has the potential to provide a universally available and reliable source of transplantable organs and alleviate the current severe shortage of donor organs.

Efforts have focused on several applications, such as the use of embryonic pancreas tissue for the treatment of insulin-dependent diabetes mellitus, and liver and spleen for the treatment of monogenic enzymatic deficiencies.

The results reported in the recent article mark an important milestone in the implementation of the Company's spleen application development plan and constitute a proof of concept for the possibility of using embryonic pig spleen transplantation to correct disease-causing genetic enzymatic deficiencies.

The publication of this study in PNAS constitutes recognition by an internationally renowned and respected academic authority of the significant scientific value of the cutting-edge work being performed by the Company-sponsored research team at the Weizmann Institute of Science, under the leadership of Prof. Reisner.

In keeping with Tissera's work plan, the multi-application research continues to advance, including experiments in pancreatic transplantation on large animal models of insulin-dependent diabetes mellitus in preparation for the initiation of human clinical studies.

The Weizmann Institute of Science press release follows.

[TABLE OMITTED]

About Tissera

Tissera is a biotechnology company dedicated to the development of novel tissue precursor regeneration technologies for treating gene deficiencies and diseases in which organ transplantation is necessary, while minimizing the dosage of immunosuppressive drugs. Tissera obtained the license for the worldwide exclusive rights to the technology developed by Professor Yair Reisner and his team at the Weizmann Institute of Science in Israel. In this research, scientists successfully implanted in mice embryonic human and porcine organ precursor tissues, which grew into functional organs. This research was published in Nature Medicine and attracted worldwide scientific and media attention.

About PNAS(Proceedings of the National Academy of Sciences of the United States of America)

PNAS is one of the world's most-cited multidisciplinary scientific serials. Since its establishment in 1914, it continues to publish cutting-edge research reports, commentaries, reviews, perspectives, colloquium papers, and actions of the Academy. Coverage in PNAS spans the biological, physical, and social sciences. PNAS is published weekly in print, and daily online in PNAS Early Edition. www.pnas.org

Safe Harbor Statement "Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding our developing technology into a useful product, our moving forward with our plans for trials, and our plans to expand the Company's infrastructure. Actual outcomes and our actual results could differ materially from those in such forward-looking statements. Such statements, including statements regarding freedom to operate, patentability, infringement, clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing that could cause actual results to differ materially include risks and uncertainties such as the inability to further finance our plans and unforeseen technical difficulties in developing our technology, which could among other things, delay or prevent product development and our planned results. For further risk factors see the Company's 10-KSB filed with the SEC for our latest fiscal year."